Also see: Vertex, AIG: Analysts' New Ratings
Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK ( TheStreet) -- STOCK COMMENTS / EPS CHANGES
Automatic Data Processing (ADP) estimates, target adjusted at Citigroup. Shares of ADP now seen reaching $58. Estimates adjusted through 2013. Mixed quarter, but strong FY12 guidance.Celgene (CELG) estimates, target increased at UBS. Shares of CELG now seen reaching $71. Estimates also increased on strong beat and raise in 2Q. Buy rating. Cerner (CERN) estimates, target increased at Goldman. CERN estimates were raised through 2013. Company is seeing higher bookings and is expanding margins. Buy rating and new $80 price target. Cerner estimates, target increased at UBS. Shares of CERN now seen reaching $65. Estimates also increased on large bookings and faster growth forecasts. Neutral rating. CME Group (CME) estimates, target higher at UBS. Shares of CME now seen reaching $325. Estimates also raised on strong 2Q and attractive growth profile. Buy rating. Expedia (EXPE) estimates, target raised at Citigroup. Shares of EXPE now seen reaching $36, according to Citigroup. Estimates also increased on solid 2Q and stable US market share. Buy rating. Expedia estimates, target increased at UBS. Shares of EXPE now seen reaching $33, UBS said. Estimates also increased on Q2 beat and conservative guidance. Neutral rating. Graco (GGG) estimates, target reduced at Goldman. Shares of GGG now seen reaching $47.50, according to Goldman Sachs. Estimates also cut, as the company is realizing a slower demand recovery. Sell rating. Goodyear (GT) estimates raised at Citigroup through 2012. Q2 beat and stronger price/mix. Maintain $22 price target and Buy rating. Starwood Hotels (HOT) estimates lowered at UBS. HOT estimates lowered through 2012. Valuation call. Maintain $70 price target and Buy rating. Interpublic (IPG) estimates, target lowered at Goldman. IPG estimates were cut through 2013. Lower sales are cutting into margins. Neutral rating and new $12 price target. KLA-Tencor (KLAC) estimates lowered at UBS through 2012. Expect 2H weakness. Maintain $49.50 price target and Buy rating.
Life Technologies (LIEF) estimates, target lowered at UBS. Shares of LIFE now seen reaching $55. Estimates also lowered on organic revenue and EPS misses. Buy rating. MetLife (MET) estimates raised at UBS through 2011. International results solid, especially top line trends. Maintain $60 price target and Buy rating. Motorola (MMI) estimates, target cut at UBS. Shares of MMI now seen reaching $31, according to UBS. Estimates also lowered as new product launches need to "stick." Buy rating. Noble Energy (NBL) numbers raised at Goldman. Shares of NBL now seen reaching $126, according to Goldman Sachs. Estimates also increased, given higher production and free cash flow results. Buy rating. NetLogic Microsystem (NETL) estimates, target lowered at UBS. Shares of NETL now seen reaching $44. Estimates also lowered as soft macro weighs on growth outlook. Buy rating. Potash (POT) estimates, target boosted at Goldman. Shares of POT now seen reaching $67. Estimates also upped, to match the company's new guidance. Buy rating. Sprint Nextel (S) estimates, target cut at UBS. Shares of S now seen reaching $5, according to UBS. Estimates also lowered on weak postpaid adds and margins in 2Q. Neutral rating. Starbucks (SBUX) estimates, target raised at UBS. Shares of SBUX now seen reaching $47. Estimates also raised on higher medium term revenue and free cash flow. Buy rating. Strayer (STRA) estimates, target reduced at Goldman. Shares of STRA now seen reaching $134, according to Goldman Sachs. Estimates also lowered, given lower enrollment rates. Neutral rating. Teradyne (TER) estimates lowered at UBS through 2011, UBS said. Working through a normal downcycle. Maintain $16 price target and Neutral rating.
End of report.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV